866-997-4948(US-Canada Toll Free)

Tuberculosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Diseases & Conditions

No. of Pages : 45 Pages


GlobalData, the industry analysis specialist, has released a new report, “Tuberculosis Therapeutics Market - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global tuberculosis therapeutics. The report identifies the key trends shaping and driving the global tuberculosis therapeutics. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. 

Most importantly, the report provides valuable insights on the pipeline products within the global tuberculosistherapeutics. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. The global tuberculosis (TB) therapeutics market was worth $99m in 2009. The market is expected to decline by 2.8% during the next seven years to reach $79m by 2017. The TB therapeutics market has been well served by antimycobacterial agents and antibiotics since the 1960s. The cure rates have been improved with the conventional DOTS (Directly Observed Treatment Short-course). Multi-Drug Resistant Tuberculosis (MDR-TB) has been a consequence of patient non-compliance and the long duration of therapy. 

Companies seem to be actively developing products for the prophylaxis and cure of TB with lesser treatment duration. The two not-for-profit organizations, TB Alliance and the Aeras Global TB Vaccine Foundation, have partnered with pharmaceutical players in order to address the burden of TB in developed and developing nations. With the success of ongoing clinical studies, the market is expected to witness a breakthrough in TB control and treatment. The vaccines’ primary focus would be to inhibit the infection in the first place. The global TB therapeutics market is heading towards a phase of decline as no launches are expected through the forecast period. 

Scope

The report provides information on the key drivers and challenges in the tuberculosis therapeutics market. Its scope includes:

  • Annualized global tuberculosis therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • The pipeline assessment shows that the tuberculosis pipeline is strong and the developmental pipeline consists of 36 first-in-class molecules, TMC 207, GSK M72, PA-824, MVA 85A/AERAS-485 and AERAS-402/Crucell Ad35 are some of the key molecules and vaccines actively progressing in clinical trials.
  • Analysis of the current and future market competition in the global tuberculosis therapeutics market. The key market players operating in this market are TB Alliance, Aeras, GSK Biologicals, Pfizer, Sanofi Aventis and others
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the tuberculosis therapeutics market
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global tuberculosis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global tuberculosis therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global tuberculosis therapeutics market landscape? - Identify, understand and capitalize
Table of Content

1 Table of contents 3

1.1 List of Tables 5
1.2 List of Figures 5

2 Tuberculosis Introduction 6
2.1 Disease Overview 6
2.2 GlobalData Pipeline Report Guidance 6

3 Tuberculosis Market Characterization 7
3.1 Tuberculosis Therapeutics Market Size 7
3.2 Tuberculosis Therapeutics Market Forecast and CAGR 7
3.3 Drivers and Barriers for the Tuberculosis Therapeutics Market 8
3.3.1 Drivers for the Tuberculosis Therapeutics Market 8
3.3.2 Barriers for the Tuberculosis Therapeutics Market 9
3.4 Opportunity and Unmet Need 9
3.5 Key Takeaway 10

4 Tuberculosis Therapeutics Market Competitive Assessment 11
4.1 Overview 11
4.2 Strategic Competitor Assessment 11
4.3 Product Profile for the Major Drugs in the Tuberculosis 12
4.3.1 Isoniazid (INH) 12
4.3.2 Rifampin (RIF) 12
4.3.3 Pyrazinamide (PZA) 13
4.3.4 Ethambutol (EMB) 13
4.3.5 Streptomycin (SM) and Other Aminoglycosides 13
4.3.6 Rifabutin 14
4.3.7 Capreomycin 14
4.4 Key Takeaway 14

5 Tuberculosis Therapeutics Market Pipeline Assessment 15
5.1 Overview 15
5.2 Strategic Pipeline Assessment 15
5.2.1 Technology Trends Analytic Framework 15
5.3 Tuberculosis Therapeutics Promising Drugs Under Clinical Development 17
5.4 Molecule Profile for Promising Drugs/Vaccines Under Clinical Development 18
5.4.1 Moxifloxacin (TB Alliance) 18
5.4.2 MVA85A/ AERAS-485 (Aeras) 20
5.4.3 AERAS-402/ Crucell Ad35 (AERAS/ Crucell) 21
5.4.4 TMC207 (Johnson & Johnson (Tibotec) /TB Alliance) 21
5.4.5 GSK M72 (GlaxoSmithKline (GSK) Biologicals/ Aeras) 22
5.4.6 PA-824 (Novartis / TB Alliance) 23
5.5 Tuberculosis Therapeutics Market Clinical Pipeline by Mechanism of Action 24
5.5.1 Tuberculosis Pipeline Pipeline by Clinical Phases of Development 25
5.5.2 Tuberculosis Therapeutics Phase III Clinical Pipeline 25
5.5.3 Tuberculosis Therapeutics Phase II Clinical Pipeline 26
5.5.4 Tuberculosis Therapeutics Phase I Clinical Pipeline 26
5.5.5 Tuberculosis Therapeutics Pre-clinical Phase Pipeline 27
5.5.6 Tuberculosis Therapeutics Discovery Pipeline 27
5.6 Key Takeaway 27

6 Tuberculosis Therapeutics Market Implications for Future Market Competition 28

7 Tuberculosis Therapeutics Market Future Players in the Tuberculosis Market 30

7.1 Introduction 30
7.2 TB Alliance, the US 31
7.2.1 Overview 31
7.2.2 Tuberculosis Portfolio 31
7.3 Aeras (Aeras Global TB Vaccine Foundation), the US 33
7.3.1 Overview 33
7.3.2 Tuberculosis Portfolio 33
7.4 Crucell, the Netherlands 35
7.4.1 Overview 35
7.4.2 Tuberculosis Portfolio 36
7.4.3 Crucell Ad35/ AERAS-402 (Crucell/ AERAS) 36
7.5 Tibotec BVBA, Belgium (A Subsidiary of Johnson & Johnson) 37
7.5.1 Overview 37
7.5.2 Tuberculosis Portfolio 37

8 Tuberculosis Therapeutics Market Appendix 39
8.1 Market Definitions 39
8.2 Abbreviations 39
8.3 Research Methodology 41
8.3.1 Coverage 41
8.3.2 Secondary Research 41
8.3.3 Forecasting 41
8.3.4 Primary Research 44
8.3.5 Expert Panel Validation 44
8.4 Contact Us 44
8.5 Disclaimer 44
8.6 Sources 45

List of Table


Table 1: TB Therapeutics Market, Global, Revenue ($m), 2001-2009 7
Table 2: TB Therapeutics, Global, Market Forecast ($m), 2009-2017 8
Table 3: TB Therapeutics Most Promising Drugs Under Clinical Development 17
Table 4: TB Therapeutics Phase III Clinical Pipeline 25
Table 5: TB Therapeutics Phase II Clinical Pipeline 26
Table 6: TB Therapeutics Phase I Clinical Pipeline 26
Table 7: TB Therapeutics Pre-clinical Phase Pipeline 27
Table 8: TB Therapeutics Discovery Pipeline 27
Table 9: TB Alliance Tuberculosis Pipeline Products 31
Table 10: Aeras Tuberculosis Pipeline Products 33
Table 11: Crucell Tuberculosis Pipeline Products 36
Table 12: Tibotec Tuberculosis Pipeline Products 37

List of Chart


Figure 1: TB Therapeutics Market, Global, Revenue ($m), 2001-2009 7
Figure 2: TB Therapeutics Market, Global, Market Forecast ($m), 2009-2017 8
Figure 3: Opportunity and Unmet Need in the TB Therapeutics Market 10
Figure 4: Strategic Competitor Assessment of the Marketed Products for Tuberculosis 11
Figure 5: Technology Trends Analytic Framework of the Tuberculosis Pipeline 16
Figure 6: Technology Trends Analytic Framework of the Tuberculosis Pipeline Description 16
Figure 7: TB Therapeutics Clinical Pipeline by Mechanism of Action 24
Figure 8: TB Therapeutics - Pipeline by Phase of Clinical Development 25
Figure 9: Implications for Future Market Competition in the TB Therapeutics Market 28
Figure 10: TB Therapeutics Market Clinical Pipeline by Company 30
Figure 11: GlobalData Market Forecasting Model 43

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *